Oppenheimer restated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Tuesday morning.

A number of other research analysts have also issued reports on BLUE. BidaskClub upgraded shares of bluebird bio from a strong sell rating to a sell rating in a research note on Friday, November 30th. Zacks Investment Research lowered shares of bluebird bio from a buy rating to a hold rating in a research note on Friday, November 30th. William Blair reiterated a buy rating on shares of bluebird bio in a research note on Tuesday. Cantor Fitzgerald set a $122.00 price target on shares of bluebird bio and gave the stock a sell rating in a research note on Monday, August 6th. Finally, Maxim Group reiterated a hold rating on shares of bluebird bio in a research note on Monday, December 3rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $194.80.

Shares of bluebird bio stock opened at $102.23 on Tuesday. bluebird bio has a 52-week low of $100.99 and a 52-week high of $236.17. The stock has a market cap of $5.95 billion, a PE ratio of -13.26 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The business had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period in the previous year, the business posted ($1.73) earnings per share. The business’s revenue was up 49.2% compared to the same quarter last year. Research analysts predict that bluebird bio will post -10.71 EPS for the current year.

In other bluebird bio news, COO Susanna Gatti High sold 1,890 shares of the company’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $113.83, for a total transaction of $215,138.70. Following the transaction, the chief operating officer now directly owns 15,610 shares in the company, valued at $1,776,886.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James Mandell sold 1,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total transaction of $150,770.00. Following the transaction, the director now owns 1,568 shares in the company, valued at $236,407.36. The disclosure for this sale can be found here. Insiders have sold 21,490 shares of company stock worth $2,901,186 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BLUE. FMR LLC lifted its holdings in shares of bluebird bio by 8.1% in the third quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock valued at $1,186,058,000 after purchasing an additional 605,797 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of bluebird bio by 8.1% in the third quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock valued at $968,610,000 after purchasing an additional 494,787 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of bluebird bio by 10.1% in the third quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after purchasing an additional 422,866 shares in the last quarter. Capital World Investors lifted its holdings in shares of bluebird bio by 37.4% in the third quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock valued at $500,150,000 after purchasing an additional 931,932 shares in the last quarter. Finally, Capital International Investors lifted its holdings in shares of bluebird bio by 188.6% in the third quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock valued at $476,053,000 after purchasing an additional 2,130,927 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Further Reading: What Does Beta Mean In Stock Selection

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.